American News ReportBiologics Do Not Raise Cancer Risk for RA PatientsAmerican News ReportBiologics (such as rituximab and anti-TNF) are made from genetically engineered proteins derived from human genes. Like DMARDS, they inhibit parts of the immune s…
|
Patents, biosimilars and trademarks – another triangle?
IAM (registration) (blog) Although Roche was taking steps to use Emcure Pharmaceuticals in India “to produce its innovative biologics in India” and to reduce the price for cancer drugs trastuzumab (Herceptin) and rituximab (MabThera), in a surprising but strategic move, Roche … |
Experts praise CLL trial for including elderly with coexisting conditionsOncology Nurse AdvisorResearchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemoth…
|
Diffuse large B-cell lymphoma: New guidelines include MYC
The Oncology Report … 70% of cells on immunohistochemistry (which equates to a “double-hit score” of 2) confers a far worse outcome than a score of 0 or 1 in patients with DLBCL undergoing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), he said. |
Medscape |
Roche’s Subcutaneous MabThera Approved in Europe
Medscape ZURICH (Reuters) – Swiss drugmaker Roche said on Friday that European regulators have approved a new timesaving formulation of its blood cancer drug MabThera (rituximab), which it hopes will help extend the medicine’s shelf life. The European … |
|
Halozyme: European Approval Of Roche’s MabThera SC For Non-Hodgkin …
NASDAQ (RTTNews.com) – Halozyme Therapeutics Inc ( HALO ) said Friday the European Commission has approved Roche’s ( RHHBY ) new subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large … |
|
Stocks Alert: Halozyme Therapeutics, Inc. (NASDAQ:HALO), EXACT Sciences …
Market News Call 28 announced that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of … |
|
Pre-market Gainers: BofI Holding, Inc. (NASDAQ:BOFI), Hansen Medical, Inc …
Gaining Green Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell … |
Drug Discovery & Development |
Roche nabs European approval for time-saving formulation of Rituxan
FiercePharma Swiss pharma giant Roche ($RHHBY) is pursuing that game plan for some of its hit biotech drugs–and today it scored a victory when European regulators approved a subcutaneous version of its cancer drug Rituxan (rituximab), known as MabThera overseas. Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News EC approves Roche’s SC formulation of MabThera for common forms of non …News-Medical.net NASDAQ –Wall Street Journal all 12 news articles » |
Drug Discovery & Development |
EC approves Roche’s SC formulation of MabThera for common forms of non …
News-Medical.net Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large … Europe OKs New Formula of Roche Cancer DrugDrug Discovery & Development Halozyme Platform Wins EC Approval for Roche’s MabThera SCGenetic Engineering News Halozyme: European Approval Of Roche’s MabThera SC For Non-Hodgkin …NASDAQ SYS-CON Media (press release) all 15 news articles » |